In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 1, 2018, Pages

  Ito, Akinobu ^a   Sato, Takafumi ^a   Ota, Merime ^a   Takemura, Miki ^a   Nishikawa, Toru ^a   Toba, Shinsuke ^a   Kohira, Naoki ^a   Miyagawa, Satoshi ^a   Ishibashi, Naoki ^a   Matsumoto, Shuhei ^a   Nakamura, Rio ^a   Tsuji, Masakatsu ^a   Yamano, Yoshinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Cefiderocol; Efflux pump; Iron transporter; Morphology; PBP; Penicillin binding protein; Porin; Time kill

Indexed keywords

CEFIDEROCOL; CEFTAZIDIME; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 3; SIDEROPHORE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARRIER PROTEIN; CELL SURFACE RECEPTOR; CEPHALOSPORIN DERIVATIVE; COLICIN RECEPTOR, E COLI; ESCHERICHIA COLI PROTEIN; MEXA PROTEIN, PSEUDOMONAS AERUGINOSA; MEXB PROTEIN, PSEUDOMONAS AERUGINOSA; OMPK35 PORIN, KLEBSIELLA PNEUMONIAE; OMPK36 PROTEIN, KLEBSIELLA PNEUMONIAE; OPRM PROTEIN, PSEUDOMONAS AERUGINOSA; OUTER MEMBRANE PROTEIN; PORIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BINDING AFFINITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG PENETRATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NON-FERMENTING GRAM-NEGATIVE BACTERIUM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; BIOSYNTHESIS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; KLEBSIELLA PNEUMONIAE; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; PORINS; PSEUDOMONAS AERUGINOSA; RECEPTORS, CELL SURFACE;

EID: 85039799071     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01454-17     Document Type: Article

References (34)

1. Kanj SS, Whitelaw A, Dowzicky MJ. 2014. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Int J Antimicrob Agents 43:170-178. https://doi. org/10. 1016/j. ijantimicag. 2013. 10. 011.
2. WHO. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO, Geneva, Switzerland. http://www. who. int/ mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/.
3. Tängdén T, Giske CG. 2015. Global dissemination of extensively drugresistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 277:501-512. https://doi. org/10. 1111/joim. 12342.
4. Foley T, Simeonov A. 2012. Targeting iron assimilation to develop new antibacterials. Expert Opin Drug Discov 7:831-847. https://doi. org/10. 1517/17460441. 2012. 708335.
5. Mollmann U, Heinisch L, Bauernfeind A, Kohler T, Ankel-Fuchs D. 2009. Siderophores as drug delivery agents: Application of the "Trojan Horse" strategy. Biometals 22:615-624. https://doi. org/10. 1007/s10534-009-9219-2.
6. Wencewicz TA, Miller MJ. 2017. Sideromycins as pathogen-targeted antibiotics. In Topics in medicinal chemistry. Springer, Berlin, Germany.
7. Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon J, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. 2015. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: Assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 59:7743-7752. https://doi. org/ 10. 1128/AAC. 00831-15.
8. Tomaras AP, Crandon JL, McPherson CJ, Banevicius MA, Finegan SM, Irvine RL, Brown MF, O'Donnell JP, Nicolau DP. 2013. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4197-4207. https:// doi. org/10. 1128/AAC. 00629-13.
9. Tomaras AP, Crandon JL, McPherson CJ, Nicolau DP. 2015. Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother 59: 2439-2442. https://doi. org/10. 1128/AAC. 04172-14.
10. Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. 26 July 2017. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens Eur J Clin Microbiol Infect Dis. https://doi. org/10. 1007/s10096-017-3063-z.
11. Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ. 2017. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72:1704-1708. https://doi. org/10. 1093/jac/dkx049.
12. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 61:e00093-17. https://doi. org/10. 1128/AAC. 00093-17.
13. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016a. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting gramnegative bacteria. J Antimicrob Chemother 71:670-677.
14. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729-734. https://doi. org/10. 1128/AAC. 01695-15.
15. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384-4386. https://doi. org/10. 1128/AAC. 03098-15.
16. McPherson CJ, Aschenbrenner LM, Lacey BM, Fahnoe KC, Lemmon MM, Finegan SM, Tadakamalla B, O'Donnell JP, Mueller JP, Tomaras AP. 2012. Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam. Antimicrob Agents Chemother 56:6334-6342. https://doi. org/10. 1128/ AAC. 01345-12.
17. Nikaido H, Rosenberg EY. 1990. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups. J Bacteriol 172:1361-1367. https://doi. org/10. 1128/jb. 172. 3. 1361-1367. 1990.
18. Tsai Y-K, Fung C-P, Lin J-C, Chen J-H, Chang F-Y, Chen T-L, Siu LK. 2011. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother 55:1485-1493. https://doi. org/10. 1128/AAC. 01275-10.
19. Tsai Y-K, Liou C-H, Fung C-P, Lin J-C, Siu LK. 2013. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. PLoS One 8:e79640. https://doi. org/10. 1371/journal. pone. 0079640.
20. Page MG, Dantier C, Desarbre E. 2010. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gramnegative bacilli. Antimicrob Agents Chemother 54:2291-2302. https:// doi. org/10. 1128/AAC. 01525-09.
21. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-A10, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria, approved standard M11-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, approved standard M45-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing, 26th informational supplement, M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenthner D, Bovee D, Olson MB, Manoil C. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 100:14339-14344. https://doi. org/10. 1073/pnas. 2036282100.
26. Alexeyev MF, Shokolenko IN, Croughan TP. 1995. Improved antibioticresistance gene cassettes and omega elements for Escherichia coli vector construction and in vitro deletion/insertion mutagenesis. Gene 160: 63-67. https://doi. org/10. 1016/0378-1119(95)00108-I.
27. Schweizer HP, Hoang TT. 1995. An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene 158: 15-22. https://doi. org/10. 1016/0378-1119(95)00055-B.
28. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomalgenes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-6645. https://doi. org/10. 1073/pnas. 120163297.
29. Mortensen JE, and Rodgers GL. 2000. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 45(Suppl S1):47-49. https://doi. org/10. 1093/jac/45. suppl-3. 47.
30. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396-7401. https://doi. org/10. 1128/AAC. 01405-16.
31. Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA, Flamm RK. 2017. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis 88:198-200. https://doi. org/10. 1016/j. diagmicrobio. 2017. 03. 011.
32. Spratt BG. 1977. Properties of the penicillin-binding proteins of Escherichia coli K12. Eur J Biochem 72:341-352. https://doi. org/10. 1111/j. 1432-1033. 1977. Tb11258. x.
33. Vashist J, Tiwari V, Das R, Kapil A, Rajeswari MR. 2011. Analysis of penicillin-binding proteins (PBPs) in carbapenem resistant Acinetobacter baumannii. Indian J Med Res 133:332-338.
34. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. 2017. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, explored in a Pseudomonas aeruginosa neutropneic murine thigh model. Int J Antimicrob Agents https://doi. org/10. 1016/j. ijantimicag. 2017. 10. 008.